All In Biotech

NDA 020786 · Chattem Sanofi

Allegra-D 12 Hour Allergy and Congestion

Fexofenadine Hydrochloride, Pseudoephedrine Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Oct 31, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Dec 24, 1997

Approved uses

4

Original approval plus efficacy supplements

Registered trials

99

15 Phase 3, 7 recruiting

FAERS reports

49

12 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 12, 2026.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchy, watery eyes ▪ itching of the nose or throat temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies reduces swelling of nasal passages temporarily relieves sinus congestion and pressure temporarily restores freer breathing through the nose

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 8, 2015 Supplement 33 · Efficacy LabelLetter
  • Jan 24, 2011 Supplement 27 · Efficacy LabelLetter
  • May 12, 2003 Supplement 14 · Efficacy · priority review LabelLetter
  • Dec 24, 1997 Original approval · Type 4 - New Combination Review
1 products under this application
  • ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION · FEXOFENADINE HYDROCHLORIDE 60MG; PSEUDOEPHEDRINE HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Fexofenadine" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product quality issue8
  • drug ineffective7
  • diarrhoea4
  • dizziness4
  • extra dose administered4
  • headache4
  • nausea4
  • chest discomfort2
  • constipation2
  • ear pain2
  • fatigue2
  • gastrointestinal disorder2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20122
201411
201513
20162
20171
20183
20222
20233
20243
20255
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 267 on PubMed

Sponsor: Chattem Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.